ZNF660 and prostate cancer: We report significant aberrant ST6GALNAC3 and ZNF660 promoter hypermethylation in PC in multiple large patient cohorts, as well as a significant association of ZNF660 hypermethylation with high risk of BCR and reduced overall survival (OS) and prostate cancer‐specific survival (CSS).